Abstract:Abstract Background Inflammatory bowel disease (IBD) has been shown to be associated with alterations in the intestinal microbiome. However, the precise nature of these microbial changes remains unclear. With billions of microbes present within the gut, novel and powerful computational techniques are required to identify the relevant shifts in microbiota contributing to the disease. Machine learning (ML) allows a data-driven approach to identify these discrete dynamic changes, while the findings of the ML algorithms can be interpreted using systems biology (SB) techniques. By combining ML and SB approaches, we aim to characterise key microbial factors in IBD pathogenesis, distinct patterns of variability in a diverse patient cohort and provide a method for patient stratification. Methods The causal relationship between the changes in the gut microbiome and IBD is difficult to establish. Data from cross-sectional studies are plagued by confounding factors and inconsistencies between cohorts. To overcome this, the authors used rich longitudinal datasets and integrated metagenomic, multi-omic and clinical patient data. This workflow has been validated using large longitudinal IBD databases, including data from IBDMDB. We assessed the performance of the ML models using well-documented performance metrics to ensure the outcomes were robust. Results As a baseline, we used multiple ML models to predict disease type (UC, CD and non-IBD) from integrated multi-omics profiles. We analysed multiple ML techniques, including linear (e.g. linear mixed model), non-linear (e.g. Random Forest), time-series models (e.g. Rotation Forest) and deep learning models (e.g. long short-term memory network model). The authors identified the models which would allow flexibility to analyse the dynamic nature of the microbiome and allow integration of the microbiome data with clinical patient data. The payoff of greater flexibility was a reduction in the model performance in terms of identifying specific features from the metagenomics that could be used as biomarkers. However, we were able to identify connections between microbial and host proteins relevant to IBD and were able to stratify these by the patient’s metagenomic data. Conclusion We have developed an integrated ml-based microbiome analysis pipeline to identify biomarkers for IBD from longitudinal metagenomic data. Furthermore, using a variety of SB approaches, we were able to interpret the predicted key microbial features and communities by inferring connections between microbial and host proteins. This pipeline will enable us to analyse vast amounts of patient microbiome data in the context of clinical and metagenomic data, to allow identification of biomarkers for disease subtypes.

Present strengths and weaknesses in current systems of comprehensive health services for children and youth.

Interleukin-17 and Inflammatory Bowel Disease: a 2-Sample Mendelian Randomization Study

The causal relationship between gut microbiota and end-stage liver disease: a bidirectional Mendelian randomization analysis

Causality Between Gut Microbiota and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study

736 - Microbiota Metabolites Short-Chain Fatty Acids Inhibit TH1 Cell Induction of Colitis Through Promoting IL-10 Production Via GPR43

Exploring the intestinal ecosystem: from gut microbiota to associations with subtypes of inflammatory bowel disease

Assessment of Causal Direction Between Gut Microbiota and Inflammatory Bowel Disease: A Mendelian Randomization Analysis

A Functional Genomics Predictive Network Model Identifies Regulators of Inflammatory Bowel Disease

Evaluating the causal effect of circulating proteome on the risk of inflammatory bowel disease-related traits using Mendelian randomization

Exploring inflammatory bowel disease therapy targets through druggability genes: a Mendelian randomization study

Gut microbiota does not play a mediating role in the causal association between inflammatory bowel disease and several its associated extraintestinal manifestations: a Mendelian randomization study

Causal role of immune cells in inflammatory bowel disease: A Mendelian randomization study

P070 Machine learning approaches to identify IBD biomarkers from longitudinal microbiome data

Mendelian randomization reveals predictive, preventive, and personalized insights into inflammatory bowel disease: the role of gut microbiome and circulating inflammatory proteins

Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease

The role of medicine in community psychiatry. A proposal.

Determine independent gut microbiota-diseases association by eliminating the effects of human lifestyle factors

The immune factors have complex causal regulation effects on inflammatory bowel disease

Association between the gut microbiota, inflammatory factors, and colorectal cancer: evidence from Mendelian randomization analysis

Associations of inflammatory cytokines with inflammatory bowel disease: a Mendelian randomization study

Association between intestinal microbiota and inflammatory bowel disease